ClinicalTrials.Veeva

Menu

Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis

F

Farabi Eye Hospital

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Adenoviral Keratoconjunctivitis

Treatments

Drug: Povidone Ophthalmic

Study type

Interventional

Funder types

Other

Identifiers

NCT04041856
farabieyehospital

Details and patient eligibility

About

Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis

Full description

Diagnosed EKC patients will be devided into two groups,first group will undergo povidone-iodine 2% eye drop four times a day and the control group will be treated only by artificial tear drops,they will be examined 3 months later and evaluations and data collections for the final comparison will be done.

Enrollment

200 estimated patients

Sex

All

Ages

17+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients suspected for viral conjunctivitis

Exclusion criteria

  • Allergic to iodized materials
  • Age under 17

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

EKC patients
Active Comparator group
Description:
Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
Treatment:
Drug: Povidone Ophthalmic
Control group
No Intervention group
Description:
All patients will undergo observational treatments including artificial tear drop and improving hygiene level

Trial contacts and locations

0

Loading...

Central trial contact

Mohammad Soleimani, professor; Arash Mirzaei, Resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems